Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

Pearl Therapeutics

Status and phase

Terminated

Phase 3

Conditions

COPD

Treatments

Drug: GFF MDI (PT003)

Drug: Placebo MDI

Study type

Interventional

Funder types

Industry

Identifiers

NCT02685293

PT003017

Details and patient eligibility

About

This is a randomized, double-blind, placebo-controlled, single-center, chronic-dosing (7 days), two-period, two-treatment, cross-over study to evaluate the treatment effect of PT003 compared with that of Placebo MDI on Cardiovascular Hemodynamics following chronic-dosing (7 days) in subjects with moderate to severe COPD.

Enrollment

4 patients

Sex

All

Ages

40 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

At least 40 years of age and no older than 80 at Visit 1.
Women of non-child bearing potential,or negative serum pregnancy test at Screening, and agrees to acceptable contraceptive methods used consistently and correctly from Screening until 14 days after final visit
Evidence of lung hyperinflation
Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
Current or former smokers with a history of at least 10 pack-years of cigarette smoking.
Pre- and Post-bronchodilator FEV1/FVC ratio must be <0.70
Post-bronchodilator FEV1 must be ≥30% to <65% predicted normal value, calculated using NHANES III reference equations.

Exclusion criteria

Significant diseases or conditions other than COPD which, in the opinion of the Investigator, may put the patient at risk
Women who are pregnant or lactating or are planning to become pregnant during the course of the study
Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma or other active pulmonary disease
Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Screening
Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to Screening or during the Screening Period
Subjects who have clinically significant uncontrolled hypertension.
Subjects with symptomatic prostatic hypertrophy that is clinically significant and not adequately controlled with appropriate therapy, in the opinion of the Investigator.
Subjects with bladder neck obstruction or urinary retention that is clinically significant in the opinion of the Investigator.
Subjects with a calculated creatinine clearance ≤30 mL/minute using Chronic Kidney Disease Epidemiology Collaboration. (CKD-EPI) formula at Screening and on repeat testing prior to Visit 2.
Subjects with abnormal liver function tests defined as AST, ALT, or total bilirubin ≥ 1.5 times upper limit of normal at Screening and on repeat testing prior to Visit 2
Subjects who have cancer that has not been in complete remission for at least five years.
Subjects with a diagnosis of glaucoma, who in the opinion of the Investigator, have not been adequately treated.
Subjects with a clinically significant ECG
Subjects who were previously enrolled in any previous PT001, PT003, or PT005 study conducted or sponsored by Pearl.